Best Genomics Companies in France
The 167 best Genomics companies in France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: DNA Script.
France's genomics sector has 167 companies tracked, $1.3B in total disclosed funding, and zero unicorns yet — which tells you something about where the opportunity clock is sitting. The global market was valued at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030, compounding at 16.37% annually, driven by falling sequencing costs and accelerating demand for personalized medicine. The rankings here sort the best Genomics companies in France by disclosed equity funding and recent momentum, so the signal is clean. Dna Script leads the directory at $315M raised, a figure that dwarfs the next contender, GenSight Biologics at $77M. That gap is real. Bpifrance, Kurma Partners, and the EIC Fund are the most active backers shaping who gets capital.
Hot themes this quarter are pharmacogenomics, machine learning drug discovery, and hereditary disease genomics, and I'd argue France is quietly building density in all three. Eligo Bioscience ($52M) and SeqOne ($26M) sit in that mid-tier that typically sees the next funding pop. Globally, conglomerates like Illumina and Thermo Fisher Scientific define the infrastructure layer, but the interesting action is further up the stack. Even outside France, Mukesh Ambani recently named genomics alongside AI and clean energy as a pillar of future growth, which signals just how mainstream the sector thesis has become. As shown in 2011 research, the foundational sequencing economics that unlocked this industry were already in motion over a decade ago. The capital is finally catching up.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in France
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNA Script Developer of benchtop DNA printer for nucleic acid synthesis | $315M | 33 mo ago | Series C | 202 | Xavier Godron Co-founder & CTO | WordPress Block EditorWordPressBugHerd+30 | 334 patents Enzymatic, template‑free nucleic acid synthesis and purification for custom DNA manufacturing | — |
| 2 | HiFiBiO Provider of a technology platform for the discovery of antibody-based drugs | $180M | 60 mo ago | Series D | 75 | Liang Schweizer Founder | — | 36 patents Ligand‑receptor pair identification and biosensor assay technologies for drug discovery | — |
| 3 | SparingVision Developer of drugs using gene therapy to treat retinitis pigmentosa | $128M | 45 mo ago | Series B | 41 | Jose Sahel Co-Founder | WordPress Block EditorwpBakeryWordPress+24 | 37 patents Ophthalmic gene/biologic therapies enhancing retinal neuron survival and light sensitivity | 2 awards |
| 4 | Dynacure Provider of antisense oligonucleotides for the treatment of rare muscular genetic disorder | $110M | 74 mo ago | Series C | 29 | Stephane Rooijen CEO | — | 3 patents Patents concentrated in chemistry & materials | — |
| 5 | GenSight Biologics Developer of viral vector-based gene therapies for retinal neurodegenerative diseases 55AI top 15%Product top 19%Funding top 20%Patents top 33% All 11 signals ▾AItop 15% Producttop 19% Fundingtop 20% Patentstop 33% Moattop 38% Innovationtop 43% Globaltop 47% Growthbottom 47% Marketbottom 41% Newsbottom 33% Techbottom 31% AI: Holds AI/ML patents (G06N-family CPC) Product: 3 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 55/100 | $77M | 3 mo ago | Public | 23 | — | WordPressMySQLPHP+12 | 89 patents Optogenetic retinal devices and AAV gene‑therapy vectors for vision restoration | 1 award |
| 6 | Stilla Technologies Developer of digital PCR solution for research | $53M | 54 mo ago | Acquired | 100 | Clement Gay Co-Founder | WordPress Block EditorWordPressMySQL+25 | — | — |
| 7 | Eligo Bioscience Developer of in vivo gene editing technology for microbiome modulation 48Patents top 16%Innovation top 19%Moat top 29%Funding top 36% All 11 signals ▾Patentstop 16% Innovationtop 19% Moattop 29% Fundingtop 36% Techtop 48% Talentbottom 49% Growthbottom 48% Globalbottom 44% Marketbottom 42% Fin. healthbottom 27% Newsbottom 22% Patents: 199 patents matched (strict assignee match) · 142 filings since 2022 vs 57 in 2017-21 Innovation: 199 patents (top 13% of patent-holders) · 142 filings since 2022 vs 57 in 2017-21 rank vs industry peers · Fliar Intelligence Index 48/100 | $52M | 13 mo ago | Series B | 44 | Xavier Duportet Co-Founder & CEO | WordPressVisual ComposerwpBakery+26 | 199 patents Targeted phage-based therapies and diagnostics for Cutibacterium acnes skin disorders | 1 job opening |
| 8 | HalioDx Developer of diagnostic product for colon cancer | $31M | 89 mo ago | Acqui-Hired | 240 | — | — | — | — |
| 9 | SeqOne Provider of bioinformatics tools for the analysis of genome sequencing data 55Growth top 32%Moat top 37%Funding top 38%Patents top 44% All 10 signals ▾Growthtop 32% Moattop 37% Fundingtop 38% Patentstop 44% Innovationtop 47% Techtop 48% Markettop 50% Talentbottom 49% Globalbottom 36% Newsbottom 20% Growth: Web rank 10,000,000 → 5,000,000 YoY · 1 acquisition/expansion move in 24 mo Moat: Editorial + unicorn rating 6/10 · IP moat: 18 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $26M | 12 mo ago | Series A | 70 | Nicolas Philippe CEO | WebflowApple iCloud MailGoogle Workspace+19 | 18 patents Bioinformatics platforms for genomic HRD detection, structural variant identification, and phenotyping support | 1 partnership |
| 10 | Da Volterra Developer of products to prevent bacterial infections triggered by antibiotic therapies | $24M | 104 mo ago | Early Stage | 16 | — | — | 164 patents Engineered probiotic yeast and oral adsorbent formulations for gut‑targeted antibiotic resistance mitigation | — |
| 11 | Lysogene Developer of gene therapies for neurodegenerative lysosomal storage disorders | $23M | 75 mo ago | Public | 22 | — | — | 16 patents AAV gene‑therapy vectors targeting lysosomal storage neurodegenerative diseases | — |
| 12 | DeepLife Provider of AI-based drug discovery and omics analysis tool for researchers 37AI top 22%Funding top 40%Moat top 45%Patents top 48% All 8 signals ▾AItop 22% Fundingtop 40% Moattop 45% Patentstop 48% Innovationtop 49% Talentbottom 49% Globalbottom 39% Marketbottom 24% AI: Classified as an AI company · Holds AI/ML patents (G06N-family CPC) Funding: Raised $16.4M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 18 mo ago | Series A | 10 | Jonathan Baptista Co-Founder & CEO | — | 4 patents Patents concentrated in computing, sensing & instrumentation | 1 award |
| 13 | IntegraGen Develops molecular diagnostic tests and genomic services. | $15M | 167 mo ago | Public | 63 | Bernard Courtieu Chief Executive Officer | — | 199 patents Predictive biomarkers and in‑vitro assays for EGFR inhibitor response in cancer patients | — |
| 14 | Genclis Developer of therapeutic, probiotic, and nutritional solutions | $14M | 197 mo ago | Series A | 22 | — | — | 28 patents Patents concentrated in health & consumer products | — |
| 15 | Meiogenix Developer of novel breeding technologies for crop plants | $13M | 54 mo ago | Series A | 7 | Luc Mathis CEO | WebflowGSAPMicrosoft Advertising+10 | 39 patents CRISPR-driven meiotic recombination tools for precise plant breeding and genetics | — |
| 16 | Rarecells Developer of noninvasive tests for earlier cancer diagnoses | $13M | 54 mo ago | Series A | 22 | — | — | 20 patents Rare cell isolation, filtration, and liquid biopsy biomarker analysis for cancer and blood disorder diagnostics | 1 partnership · 1 award |
| 17 | Annapurna Therapeutics Developer of adeno-associated virus (AAV) mediated gene therapies for rare diseases | $12M | 146 mo ago | Acquired | — | Amber Salzman ex-CEO | — | — | — |
| 18 | GenOway Provider of transgenic rodent models and customized cell lines for preclinical development | $12M | 77 mo ago | Public | 124 | — | WebflowMatomo AnalyticsGoogle Analytics+16 | 15 patents Genetically engineered animal models with conditional KO/KI and advanced cloning vectors | 1 partnership |
| 19 | Flash Therapeutics Provider of gene-based therapeutics for multiple disorders | $12M | 59 mo ago | Series A | 49 | — | — | 37 patents Apelin-based lymphedema therapy and viral RNA/genome‑editing delivery platforms | — |
| 20 | TcLand Expression Developer of diagnostic solutions for immune-mediated disorders and transplant patients | $11M | 89 mo ago | Acqui-Hired | 11 | Huseyin Firat President & CEO | — | — | — |
| 21 | WhiteLab Genomics Provider of drug discovery and development platform | $10M | 45 mo ago | Series A | 29 | David Del Bourgo CEO co-founder | SkolengoSentryApple iCloud Mail+20 | 4 patents ML-driven phenotype prediction and cell‑surface protein identification for functional genomics | — |
| 22 | PathoQuest Provider of next-generation sequencing for microbiology testing | $10M | 55 mo ago | Acquired | 48 | — | WordPressMySQLPHP+29 | 68 patents Clinical diagnostics for microbial viability and anellovirus-based immune suppression biomarkers | — |
| 23 | Plant Advanced Technologies Plant biotechnology company producing rare actives for cosmetic, pharmaceutical, agrochemical markets | $10M | 61 mo ago | Public | 59 | — | WordPressMySQLPHP+27 | 64 patents Botanical root extracts and bioactive compounds for cosmetics, pharmaceuticals, and affinity assays | — |
| 24 | Genomic Vision Nanotechnology for single DNA analysis for cancer and acute disease molecular diagnostics | $9M | 133 mo ago | Public | 37 | Aaron Bensimon Founder & CEO | — | 108 patents Detecting viral DNA integration and telomere analysis using molecular combing technologies | — |
| 25 | ProteoGenix Provider of custom synthesis and analytical services | $8M | 194 mo ago | Series B | 7 | Philippe Funfrock CEO | WordPressMySQLPHP+35 | — | — |
| 26 | Scipio Bioscience Develops sample preparation solutions | $8M | 36 mo ago | Series A | 44 | Pierre Walrafen Co-Founder & CEO | — | 19 patents Hydrogel-based spatial omics platforms for single-cell capture and barcoding | — |
| 27 | Biomemory Online platform offering bio-digital data storage solutions | $5M | 18 mo ago | Series A | 10 | Erfane Arwani Co-Founder & CEO | WebflowGSAPLenis+15 | — | — |
| 28 | Polyplus Transfection Transfection Solutions for Healthcare and Life Sciences organizations | $5M | 185 mo ago | Acquired | 139 | — | — | 119 patents Non‑viral nucleic acid delivery reagents and purification methods for gene/mRNA transfection | — |
| 29 | One Biosciences Developer of single-cell therapeutics solutions to treat multiple health disorders | $5M | 11 mo ago | Series A | — | Celine Vallot Co-Founder | WordPressMySQLPHP+7 | — | 1 partnership · 2 awards |
| 30 | OncoDiag Developer of non-invasive cancer diagnostic solutions | $4M | 63 mo ago | Series A | 5 | Claude Hennion Co-Founder & President & CEO | — | 12 patents Molecular diagnostic assays for cancer, especially bladder cancer detection and monitoring | — |
| 31 | DNA Therapeutics Developer of DNA molecules for cancer therapy | $4M | 188 mo ago | Acquired | 10 | — | — | 25 patents Patents concentrated in health & consumer products | — |
| 32 | Brink Therapeutics Developer of cell and gene therapies to treat various diseases | $4M | 14 mo ago | Seed | — | Jonathan Naccache Co-Founder & CEO | Cart FunctionalitySquarespace CommerceSquarespace+12 | — | — |
| 33 | Novacyt A molecular diagnostics company specializing in genomic medicine solutions | $4M | 96 mo ago | Public | 222 | — | WordPressApple iCloud MailMySQL+25 | 133 patents Automated sample prep and digital cytology/histology analysis for cellular diagnostics | — |
| 34 | ImmunID Molecular diagnostics using immune profiling | $3M | 204 mo ago | Deadpooled | — | Nicolas Pasqual Co-Founder & CSO | — | 21 patents Immune repertoire sequencing to predict lymphoma risk and checkpoint‑inhibitor response. | — |
| 35 | QUIDDITAS Developer of genome editing-based therapies with genetic recombination technology | $3M | 13 mo ago | Seed | — | Francois Cherbonneau Co-Founder & CEO | — | — | — |
| 36 | LXRepair Provider of multiplexed assays for determination of the enzymatic status of cellular DNA repair | $3M | 85 mo ago | Seed | 7 | Sylvie Sauvaigo Founder & CEO | — | 7 patents DNA repair profiling assays for tumor radiosensitivity and toxicity prediction | — |
| 37 | MitoProd Developer of technology for the production of ribonucleic acids | $3M | — | Deadpooled | — | Guillaume Plane Founder & CEO | — | — | — |
| 38 | ScreenCell Developer of circulating tumor cells | $3M | 113 mo ago | Funding Raised | 11 | — | — | 32 patents Microfluidic biomarker assays for circulating tumor cell detection and sickle‑cell diagnostics | — |
| 39 | Epigene Labs Developer of drugs through precision oncology | $3M | 46 mo ago | Seed | 25 | Akpeli Nordor Co-Founder | WordPressMySQLPHP+22 | — | — |
| 40 | BforCure Developer of a PCR device for pathogen detection | $2M | 36 mo ago | Seed | 55 | — | — | 34 patents Integrated microwave sample‑lysis and multiplex real‑time PCR diagnostic platforms | — |
| 41 | Minos Biosciences Developer of a sequencing-based multi-omic analysis device | $2M | 62 mo ago | Seed | 11 | Hubert Geisler Co-founder & Head of Microfluidics | — | — | — |
| 42 | En Carta Developer of molecular diagnostic tests for infectious diseases | $2M | 24 mo ago | Seed | 3 | Margot Karlikow Co-Founder | — | — | 1 job opening · 1 partnership |
| 43 | GreenTropism Provider of software components for mainstream and industrial spectroscopy | $1M | 106 mo ago | Seed | 13 | Anthony Boulanger Founder & CEO | — | 31 patents Rapid pathogen detection in biological fluids using surface-enhanced Raman spectroscopy | — |
| 44 | Bilhi Genetics Disease prediction algorithms using genetic markers | $1M | 124 mo ago | Seed | 11 | Bruno Dessein Co-Founder | — | — | — |
| 45 | Acobiom Developer of diagnostics for personalized medicine applications and provided omics services | $1M | 64 mo ago | Early Stage | 7 | David Piquemal Co-Founder & CSO | WordPressMySQLPHP+24 | 26 patents Predictive biomarkers for pancreatic cancer survival prognosis | — |
| 46 | Millidrop Provider of cell culture machines based on milli fluidics technology for bacteriological research | $1M | 93 mo ago | Seed | 5 | — | — | — | — |
| 47 | Alma Bio Therapeutics Developer of immunomodulatory drugs for the treatment of autoimmune diseases | $1M | 78 mo ago | Seed | 6 | — | — | — | — |
| 48 | Firalis Provider of biomarker-based diagnostics products | $549K | 67 mo ago | Seed | 41 | — | anime.jsGoogle Font APIMicrosoft 365+6 | 5 patents RNA-based biomarkers and therapeutics for cardiac disease and toxicity assessment | — |
| 49 | Hiphen Provider of agricultural imaging solutions and plant phenotyping data platform | $491K | 37 mo ago | Funding Raised | 28 | — | WordPressTypeScriptPHP+33 | — | — |
| 50 | Plantik Biosciences Developer of plant engineering workflow to create climate-resilient and thermotolerant plants | $100K | 25 mo ago | Seed | 6 | Aditya Nayak Co-Founder & CTO | Cart FunctionalitySquarespace CommerceSquarespace+10 | 2 patents Plant genome editing methods for precise genetic modification of crops | 1 expansion |
Top 12 Genomics companies in France
#1
Public · Paris, Ile de France · founded 2011 · 23 employees$76.6Mraised▾
Developer of viral vector-based gene therapies for retinal neurodegenerative diseases. The company develops innovative approaches to prevent retinal degeneration in selected pathological conditions, to restore vision in patients suffering from very low vision or blindness. Its lead product candidates include GS010, an AAV2 containing the human wild-type ND4 gene for the treatment of Leber Hereditary Optic Neuropathy associated with a mutation in the ND4 gene, and GS030 which comprises a gene encoding a photoactivatable channelrhodopsin for the treatment of retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration.
- Mar 2026Post IPO$2M
- Dec 2025Post IPO$3.4M
- Nov 2025Post IPO$2.3M
- Oct 2025Post IPO$4.3M
#2
Series B · Paris, Ile de France · founded 2014 · 44 employees$52.3Mraised▾
Developer of in vivo gene editing technology for microbiome modulation. The company offers a platform to edit the microbiome's gene repertoire. This platform aims to address diseases triggered or aggravated by specific bacterial genes. The technology targets the interactions between the microbiome and the host's immune system.
- May 2025Grant (prize money)$5M
- Nov 2023Series B$30.1M
- Mar 2022Grant (prize money)$55.7K
- Apr 2019Grant (prize money)$3.1M
#3
Series A · Montpellier, Occitanie · founded 2017 · 70 employees$26.1Mraised▾
Provider of bioinformatics tools for the analysis of genome sequencing data. The platform helps researchers to detect & identify the variants responsible for gene mutation. It helps to detect many types of variants such as SNPs, Indels, CNVs, and mid-sized deletions.
- May 2025Series A$22.7M
- Jan 2022Series A$22.7M
- Mar 2019Series A$3.4M
#4
Series A · Paris, Ile de France · founded 2020$5Mraised▾
Developer of single-cell therapeutics solutions to treat multiple health disorders. The company's proprietary platform uses single-cell RNA and DNA sequencing that helps to analyze disease-causing agents and provides treatment solutions. The company has developed single-cell computational software for the analysis of genomic data.
- Jul 2025Series A$17.4M
- Sep 2022Series A$5M
#5
Series C · Paris, Ile de France · founded 2014 · 202 employees$315Mraised▾
DNA script is a developer of a benchtop DNA printer powered by enzymatic technology for nucleic acid syntheis. It is offering a benchtop DNA printer that provides outsourced chemical-based DNA synthesis through enzymatic synthesis technology to synthesize DNA.
- Sep 2023Grant (prize money)$4.3M
- Jan 2022Series C$35M
- Oct 2021Series C$165M
- Sep 2021Grant (prize money)$280K
#6
Series A · Paris, Ile de France · founded 2019 · 10 employees$16.4Mraised▾
Provider of AI-based drug discovery and omics analysis tool for researchers. The company has developed tools that are AI-enabled for the process of drug discovery. The tool assists in provided insights for target protein for the drug for an individual patient. The tools use machine learning technology to identify molecular triggers for the drug and target identification. It has features to process biological data, tools for genomic screening, and more.
- Dec 2024Series A$10.5M
- Oct 2022Series A$5.9M
#7
Seed · Paris, Ile de France · founded 2024$4Mraised▾
Developer of cell and gene therapies to treat various diseases. The company is developing next-generation recombinases ultra-precise and efficient enzymes that surpass CRISPR-Cas9 to revolutionize cell and gene therapies, enabling large-scale production to treat cancer, genetic disorders, and other diseases.
- Apr 2025Seed$4M
#8
Seed · Montlhery, Ile de France · founded 2021$2.9Mraised▾
Developer of genome editing-based therapies with genetic recombination technology. It offers CRISPR-based genome editing technology for developing therapeutics for red blood diseases.
- May 2025Seed$1M
- May 2025Grant (prize money)$1.9M
#9
Series A · Paris, Ile de France · founded 2021 · 10 employees$5.2Mraised▾
Online platform offering bio-digital data storage solutions. The platform is developing a petrol-free DNA synthesis and copy process based on synthetic biology for data storage. It also allows the production of long, bio-sourced, biocompatible, and bio-secure DNA fragments that can be stored as inert polymers for thousands of years without any energy input.
- Dec 2024Series A$18M
- Nov 2022Seed$5.2M
#10
Series B · Paris, Ile de France · founded 2016 · 41 employees$128.1Mraised▾
Developer of drugs using gene therapy to treat retinitis pigmentosa. The company discovers and develops genetic medicine which is used to prevent the degeneration of cones cells in the retina to treat inherited retinal diseases. The company develops a single-injection dosage form for gene therapy.
- Sep 2022Series B$75.5M
- Jul 2021Grant (prize money)$59.4K
- Oct 2020Series A$52.5M
- Aug 2019Grant (prize money)$2.7M
#11
Series D · Paris, Ile de France · founded 2013 · 75 employees$179.5Mraised▾
Provider of a technology platform for the discovery of antibody-based drugs. The platform combines high throughput, single-cell, functional-based screening of entire B cell (Ab producing cells) populations with next-generation sequencing and rapid DNA synthesis for rare antibody drugs.
- Jun 2021Series D$75M
- Aug 2019Series C$67M
- May 2018Series B$37.5M
- Series A—
#12
Acquired · Villejuif, Ile de France · founded 2013 · 100 employees$53.1Mraised▾
Developer of digital PCR solution for research. The system works on the principle of Crystal Digital PCR in a compact and reliable digital PCR solution with a single consumable. The device is assisted by Crystal Miner software for analyzing the generated data and identifying positive and negative droplets for all 3 fluorescence channels.
- Nov 2021Conventional Debt$22.5M
- Nov 2021Series B$12.7M
- Feb 2020Series B$22.1M
- Nov 2018Series A$18.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in France
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,937 France-affiliated papers.
- Centre National de la Recherche Scientifique581
- Inserm393
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement130
- Assistance Publique – Hôpitaux de Paris112
- European Molecular Biology Laboratory87
- Genome15→94
- Gene20→91
- Transcriptome2→53
- Chromatin2→28
- Identification (biology)2→27
- Gene4→56
- Transcriptome3→39
- Genome5→24
- Biomarker1→17
- In silico1→16
- Disease3→34
- Gene1→19
- Cancer2→17
- Clinical trial2→16
- Immune system2→14
Where bioinformatics is researched across France
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in France
France bioinformatics patent filing is steady — 2 filings from 4 assignees (2024–2025), led by UNIV Paris CITE, Centre NAT RECH Scient, Ecole NAT Superieure DE Chimie P; annual filings 1→1.
- UNIV Paris CITE2
- Centre NAT RECH Scient2
- Ecole NAT Superieure DE Chimie P1
- Ecole NAT Superieure DE Chimie D1
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.